Press Release

Genetic Signatures has issued a Supplementary Prospectus to extend the closing date of its IPO to 5.00pm (AEDT) on 20 March 2015. This Supplementary Prospectus supplements, and must be read together with, the Prospectus dated 7 November 2014 (“Prospectus”) relating to an offer of Shares by the Company. The prospectus and supplementary prospectus may be…

Exciting Australian Biotech offers Institutional & Retail Shareholders Access to Global $5.3B Molecular Diagnostics Market Sydney, Australia – 18 November 2014: Genetic Signatures Ltd has launched its prospectus offering institutional and retail investors the opportunity to invest in the exciting growing global molecular diagnostics market prior to the Company’s listing on the Australian Stock Exchange on…

Sydney, Australia 30th October 2014 Genetic Signatures Ltd today announced the appointment of Pat Noland to its Board of Directors in the capacity of non-executive director. Mr. Noland currently serves as Chief Executive Officer of StrataDx, a leading provider of high-quality pathology services in the dermatology, urology, podiatry, oral pathology, gastroenterology, and gynecology segments. Mr.…

Genetic Signatures has increased its suite of CE- marked IVD products with the registration of the EasyScreen™ Enteric Bacteria Detection Kit. The EasyScreen™ Enteric Bacteria Detection Kit is a real-time PCR kit for the detection of i) Salmonella spp., (ii) Campylobacter spp., (iii) Shigella spp., (iv) Yersinia enterocolitica, (v) toxigenic C. difficile and (vi) Listeria…

Genetic Signatures has recently appointed Mike Aicher to the company’s Board of Directors as Executive Director – U.S. Operations. Mr. Aicher was CEO of National Genetics Institute (NGI), a company he co-founded in 1991, that later became a wholly owned subsidiary of Laboratory Corporation of America (LabCorp). More recently, Mr. Aicher led LabCorp’s Western Division…

We are pleased to announce that we have been granted TGA approval for our first IVDs in Australia. The following products are now listed on the Australian Register of Therapeutic Goods (ARTG). [table id=23 /]   The next products that will be registered are SP003 EasyScreen™ Sample Processing Kit  (Mag Beads) and EV001 (& HT) EasyScreen™ Enteric Viral Detection Kit.

Two recent publications highlight the clinical performance of Genetic Signatures EasyScreen™ Enteric Pathogen Detection Assays. The most recent publication by Stark et al. evaluates the clinical performance of the EasyScreen™ Enteric Protozoan Detection Kit. Stark D, Roberts T, Marriott D, Harkness J. Evaluation of the EasyScreen™ Enteric Parasite Detection Kit for the detection of Blastocystis spp., Cryptosporidium spp., Dientamoeba fragilis, Entamoeba complex, and Giardia intestinalis from clinical stool samples. Diagnostic Microbiology…

Genetic Signatures will be presenting and exhibiting at The Australian Society for Microbiology, Annual Scientific Meeting, from 6 – 9 July 2014 in Melbourne, Australia. The Australian Society for Microbiology Annual Scientific Meeting is the largest microbiology conference held in Australia and attracts approximately 600 microbiologists, allied professionals, researchers and academics from across the country…

Genetic Signatures will exhibit at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in Barcelona, Spain from the 10th to the 13th of May 2014. ECCMID provides a forum for delegates to update their knowledge and learn about the latest innovations in the field of infectious diseases and…